INO
Inovio Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$93.83M
P/E Ratio
—
EPS
$-1.81
Beta
1.70
52W High
$2.98
52W Low
$1.03
50-Day MA
$1.49
200-Day MA
$1.87
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
16.58
PEG Ratio
0.00
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA drugs to treat and protect people from diseases associated with the human papillomavirus (HPV), cancer, and infectious diseases.
Fundamentals
| Revenue (TTM) | 65,340 |
| Gross Profit (TTM) | $-54.14M |
| EBITDA | $-85.40M |
| Operating Margin | -132871.00% |
| Return on Equity | -183.50% |
| Return on Assets | -57.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.35 |
| Price-to-Book | 3.96 |
| Price-to-Sales (TTM) | 1435.97 |
| EV/Revenue | 708.84 |
| EV/EBITDA | -1.09 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $81.59M |
| Float | $68.80M |
| % Insiders | 0.42% |
| % Institutions | 42.11% |
Analyst Ratings
Consensus ($6.97 target)
2
Strong Buy2
Buy2
HoldData last updated: 4/29/2026